作为呼吸和免疫学转化科学和实验医学(TSEM)副总裁&I) at AstraZeneca, I am part of the R&I leadership team spanning the UK, Sweden and US. 我设计并推出了TSEM，以提供从新靶点到疾病病理学和生物标志物的路线图, with precision medicine from the start, 强调了解常见慢性疾病异质性的重要性.
澳门第一赌城在线娱乐已经有一些分子在临床开发中，澳门第一赌城在线娱乐正在积极开发一些针对常见慢性疾病的精准医学的第一批例子.
Previously, 担任澳门在线赌城娱乐基因组学研究中心基因组学投资组合全球主管, 我在获得4亿多美元投资以整合多达200万患者的基因组序列和临床数据方面发挥了关键作用. 其他关键业务交付包括澳门在线赌城娱乐在2018年12月获得欧盟CE-IVD认证的首个呼吸诊断, FDA批准了一种用于监测降尿酸疗法有效性的PoC血清尿酸仪.
我在利物浦大学完成了分子遗传学博士学位，并发表了40多篇同行评议的文章, most recently in the New England Journal of Medicine, Nature and Nature Reviews Drug Discovery.
我很荣幸有机会与澳门在线赌城娱乐众多才华横溢的科学家和团队一起应用强大的科学技术，带来改变生活的药物，改善患者的生活.
Award
Award
Award
Award
Key Achievements
Featured publications
Diagnostic utility of exome sequencing for kidney disease.
Groopman, E. et al, Platt, A*, Goldstein, D.B., Gharavi, A.G. (2018) New England Journal of Medicine, DOI: 10.1056/NEJMoa1806891
*Joint senior author as stated in paper
Drug development in the era of precision medicine.
Dugger S, Platt A, Goldstein D, (2018), Nature Reviews Drug Discovery 17 (3):183-196.
An analytical 和parison between point-of-care uric acid testing meters.
Paraskos J, Berke Z, Cook J, Miner JN, Braddock M, Platt A, Hughes G， (2016) Expert Review of Molecular Diagnostics. 16(3):373-382. DOI:10.1586/14737159.2016.1134326.
Rheumatoid arthritis: a case for personalized health care?
Platt A, Karsdal M A, Bay-Jensen A C, (2014), Arthritis Care and Research 66(9):1273-80.
A retrospective analysis of RET translocation, 在四项随机III期研究中，万德替尼治疗的NSCLC患者的基因拷贝数增加和表达.
Platt A, Morten J, Ji Q, Elvin P, Womack C, Su X, Donald E, Gray N, Read J, Bigley G, Blockley L, Cresswell C, Dale A, Davies A, Zhang T, Fan S, 始点, Gladwin A, Harrod G, Stevens J, Williams V, 叶问, Zheng L, de Boer R, Herbst RS, Lee JS, Vasselli J, (2015), 1. BMC Cancer. 15(1):171.
翻译生物标志物和离体关节组织模型作为类风湿关节炎药物开发的翻译工具.
Kjelgaard-Petersen CF, Platt A, Braddock B, Jenkins M, Musa K, Graham E, Keeler S, Slynn G, Weinblatt ME, Karsdal MA, Bay-Jensen AC, (2018), Arthritis and Rheumatology, 70(9):1419-1428
关节组织周转的血清学生物标志物在基线时预测托珠单抗的反应.
Bay-Jensen AC, Byrjalsen I, Siebuhr AS, Christiansen C, Platt A, Karsdal MA， (2014); Journal of Clinical Rheumatology. 20(6):332-335.
IL-6通路驱动的类风湿关节炎对IL-6受体抑制反应的研究.
Wang J, Platt A, Benayed R, Germer S, Lei G, Rabe C, Benayed R, Kenwright A, Hemmings A, Martin M, Harari O, (2013), British Medical Journal Open 2013;3:e003199. doi:10.1136/bmjopen-2013-003199.
类风湿关节炎结构损伤快速进展者的血清学鉴定.
Siebuhr AS, Bay-Jensen AC, Leeming D.J, Platt A, Byrjalsen I, Christiansen C, van de Heijde D, Karsdal MA (2013)， Arthritis Research & Therapy 15:R86 doi:10.1186/ar4266.
全基因组关联分析表明八个位点与tocilizumab治疗类风湿性关节炎的应答有关.
Wang J, Bansal AT, Martin M, Germer S, Benayed R, Essioux L, Lee JS, Begovich A, Hemmings A, Kenwright A, Taylor KE, Upmanyu R, Cutler P, Harari O, Marchini J, Criswell LA, Platt A, (2012), The Pharmacogenomics Journal 13:235-241.
IL-6受体抑制正调节对抗肿瘤坏死因子治疗反应不充分的类风湿关节炎患者的骨平衡:托珠单抗辐射研究中骨代谢的生化标志物分析.
Karsdal MA, Schett G, Emery P, Harari O, Byrjalsen I, Kenwright A, Bay-Jensen AC, Platt A， (2012)， Seminars in Arthritis and Rheumatism 42(2):131-9.
Gilbert综合征典型UGT1A1基因变异与接受托珠单抗患者的非共轭高胆红素血症相关.
Lee JS, Wang J, Martin M, Germer S, Kenwright A, Benayed R, Spleiss O, Platt A, Pilson R, Hemmings A, Weinblatt ME, Kaplowitz N, Krasnow J, (2011), Pharmacogenet Genomics. 21(7):365-74.
在转录诱导剂中插入两个氨基酸将其转化为半乳糖激酶.
Platt A, Ross H, Hankin S, Reece RJ, (2000), Proceedings of the National Academy for Sciences 97 (7): 3154-3159.
酵母半乳糖遗传开关是由Gal4p/Gal80p/Gal3p复合物的形成介导的.
Platt A, Reece RJ, (1998), The EMBO Journal 17 (14): 4086-4091
氮代谢物抑制涉及曲霉转录因子AREA的c端和GATA结构域及其mRNA的3'-未翻译区.
Platt A, Langdon T, Arst HN, Kirk D, Tollervey D, Mates Sanchez JM, Caddick MX， (1996)， The EMBO Journal 15 (11): 2791-2801.
Veeva ID: Z4-51856
Date of preparation: January 2023